20 products added to the Discount Not Deducted (DND) list from September 2022
Following applications made by PSNC to the Department of Health and Social Care (DHSC) and the NHS Business Services Authority (NHSBSA), a further 20 new products entered the list of ‘Drugs for which Discount is Not Deducted’ (DND) in Part II of the Drug Tariff from 1 September 2022:
- Acetylcysteine 200mg oral powder sachets
- Alzest 13.3mg/24hours transdermal patches
- Brilique 60mg tablets
- Brilique 90mg orodispersible tablets
- Brilique 90mg tablets
- Cenobamate 12.5mg tablets and Cenobamate 25mg tablets
- Cenobamate 50mg tablets
- Cenobamate 100mg tablets
- Cenobamate 150mg tablets
- Cenobamate 200mg tablets
- Creon 25000 gastro-resistant capsules
- Creon Micro Pancreatin 60.12mg gastro-resistant granules
- Hydrocortisone 2.5% cream
- Hydrocortisone 2.5% ointment
- Icosapent 998mg capsules
- Imiquimod 5% cream 250mg sachets
- Valsartan 40mg tablets
- Voriconazole 100mg tablets
- Voriconazole 50mg tablets
- Zyclara 3.75% cream 250mg sachets
For a list of all the monthly changes to the DND status of products please see the following page Notice of changes to discount not deducted (DND) status of products. A total of 549 products have been granted DND status following checks made by PSNC within the past 27 months.
Background
The DND list is updated monthly by the DHSC and includes grouped and individual items. Individual items are separately listed in Part II of the Drug Tariff. Any items covered by the ‘Group Items’ heading are not listed again individually in Part II. Contractors can also check the Actual Medicinal Product (AMP) listing on Dictionary of Medicines and Devices (dm+d) to identify whether a product meets the DND criteria (see below).
Group items
Any products that are covered by one or more of the Group items categories below are reimbursed without any discount deduction applied.
- Cold Chain Storage (ALL)
- Schedule 1, 2 or 3 Controlled Drugs: Products containing drugs listed in Schedules 1, 2 and 3 of the Misuse of Drugs Regulation 2001
- Cytotoxic or Cytostatic item (ALL):
- Immunoglobulins (ALL)
- Insulins for injection (ALL)
- Vaccines and antisera (ALL)
- Unlicensed medicines: ‘Specials’ not listed in Part VIIIB where the product has been sourced from a supplier holding a MHRA specials or importers licence (prescriptions must be endorsed with invoice price less discount/rebate)
- Hazardous chemicals
Individual items
Products that do not are covered by one or more of the Group item categories above must fulfil all three of the following criteria to qualify for entry to the DND list.
- the manufacturer(s), AAH and Alliance do not offer pharmacy contractors a discount
- fewer than 500,000 items per year are dispensed of the product
- average net ingredient cost (NIC) per item is more than £50
PSNC will continue its work to assess whether other drugs and appliances fulfil the current DND entry requirements under either the ‘Group’ and ‘Individual item’ criteria and make applications to NHSBSA and DHSC, accordingly.
If a product is currently subject to the discount deduction scale and you believe that it should be added to DND list based on the criteria specified above, please contact the PSNC Dispensing and Supply Team by emailing info@cpe.org.uk who will investigate whether the product meets the relevant DND criteria and make an application to the DHSC and NHSBSA, as appropriate.
For further information on how discount deduction works, click here.
